Dosimetry in peptide receptor Radionuclide therapy (PRRT) using Lu-177 DOTA-TATE: Intra- and interpatient variability

被引：0
|
作者：
Wehrmann, C. [1 ]
Senftleben, S. [1 ]
Baum, R. P. [1 ]
机构：
[1] Zentralklin Bad Berka GmbH, Bad Berka, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2007年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S178 / S179
页数：2
相关论文
共 50 条
  • [41] Mixed model time-activity fitting to reduce SPECT/CT imaging time points for dosimetry in Lu-177 peptide receptor radionuclide therapy (PRRT)
    Devasia, Theresa
    Dewaraja, Yuni
    Schipper, Matthew
    Wong, Ka Kit
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [42] Dynamic Tumour Dosimetry Model for Peptide Radionuclide Therapy with 177Lu-DOTA-Octreotate
    Konijnenberg, M. W.
    Bernard, B. F.
    De Jong, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S101 - S101
  • [43] Preparation of DOTA-TATE and DOTA-NOC freeze-dried kits for formulation of patient doses of 177Lu-labeled agents and their comparison for peptide receptor radionuclide therapy application
    Tapas Das
    Mohini Bhadwal
    Sharmila Banerjee
    H. D. Sarma
    Ajit Shinto
    K. K. Kamaleshwaran
    Journal of Radioanalytical and Nuclear Chemistry, 2014, 299 : 1389 - 1398
  • [44] Intravenous and intra-arterial peptide receptor radionuclide therapy (PRRT) using Y-90-DOTA-Tyr3-OCTREOTATE (Y-90 DOTA-TATE) in patients with metastatic neuroendocrine tumors
    Baum, RP
    Söldner, J
    Schmücking, M
    Niesen, A
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S238 - S238
  • [45] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; dosimetric findings
    Mok, S.
    Tay, Y.
    Ng, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S532 - S532
  • [46] Preparation of DOTA-TATE and DOTA-NOC freeze-dried kits for formulation of patient doses of 177Lu-labeled agents and their comparison for peptide receptor radionuclide therapy application
    Das, Tapas
    Bhadwal, Mohini
    Banerjee, Sharmila
    Sarma, H. D.
    Shinto, Ajit
    Kamaleshwaran, K. K.
    JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, 2014, 299 (03) : 1389 - 1398
  • [47] Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival
    Loeser, Anastassia
    Schwarzenboeck, Sarah M.
    Heuschkel, Martin
    Willenberg, Holger S.
    Krause, Bernd J.
    Kurth, Jens
    NUCLEAR MEDICINE COMMUNICATIONS, 2018, 39 (03) : 236 - 246
  • [48] Re-challenge Peptide Receptor Radionuclide Therapy using the SSTR Antagonist Lu-177 DOTA-JR11: Pilot Results assessing Dosimetry, Safety and Response
    Kulkarni, H.
    Schuchardt, C.
    Robiller, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S248 - S248
  • [49] Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions
    del Olmo-Garcia, Maria I.
    Prado-Wohlwend, Stefan
    Bello, Pilar
    Segura, Angel
    Merino-Torres, Juan F.
    CANCERS, 2022, 14 (03)
  • [50] Treatment with tandem [90Y]DOTA-TATE an [177Lu]DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results
    Seregni, E.
    Maccauro, M.
    Coliva, A.
    Castellani, M. R.
    Bajetta, E.
    Aliberti, G.
    Vellani, C.
    Chiesa, C.
    Martinetti, A.
    Bogni, A.
    Bombardieri, E.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 54 (01): : 84 - 91
12345